Based on the key indicators related to Bone Biologics' liquidity, profitability, solvency, and operating efficiency, Bone Biologics Corp is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April. At this time, Bone Biologics' Total Stockholder Equity is fairly stable compared to the past year. Net Working Capital is likely to climb to about 3.7 M in 2025, whereas Common Stock Shares Outstanding is likely to drop slightly above 1.3 M in 2025. Key indicators impacting Bone Biologics' financial strength include:
Investors should never underestimate Bone Biologics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Bone Biologics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Bone Biologics Corp.
Net Income
(7.69 Million)
Bone
Select Account or Indicator
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Interest Coverage
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Shareholders Equity Per Share
Debt To Equity
Graham Net Net
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Cash Ratio
Cash Conversion Cycle
Cash Flow Coverage Ratios
Price To Book Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Begin Period Cash Flow
Other Cashflows From Financing Activities
Other Non Cash Items
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change In Working Capital
Stock Based Compensation
Depreciation
Issuance Of Capital Stock
Common Stock Shares Outstanding
Total Assets
Net Debt
Cash
Cash And Short Term Investments
Liabilities And Stockholders Equity
Total Current Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Retained Earnings
Other Stockholder Equity
Total Liab
Common Stock
Short Long Term Debt Total
Other Current Assets
Short Term Debt
Property Plant And Equipment Net
Accounts Payable
Non Current Assets Total
Net Receivables
Non Current Liabilities Total
Accumulated Other Comprehensive Income
Net Invested Capital
Net Working Capital
Capital Stock
Other Operating Expenses
Operating Income
Ebit
Ebitda
Total Operating Expenses
Income Before Tax
Gross Profit
Cost Of Revenue
Depreciation And Amortization
Selling General Administrative
Research Development
Total Other Income Expense Net
Income Tax Expense
Interest Expense
Tax Provision
Net Interest Income
Net Income From Continuing Ops
Probability Of Bankruptcy
Understanding current and past Bone Biologics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Bone Biologics' financial statements are interrelated, with each one affecting the others. For example, an increase in Bone Biologics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Bone Biologics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bone Biologics Corp. Check Bone Biologics' Beneish M Score to see the likelihood of Bone Biologics' management manipulating its earnings.
Bone Biologics Stock Summary
Bone Biologics competes with Bone Biologics, and Inspira Technologies. Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts. Bone Biologics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 1 people.
The reason investors look at the income statement is to determine what Bone Biologics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Bone Biologics's current stock value. Our valuation model uses many indicators to compare Bone Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bone Biologics competition to find correlations between indicators driving Bone Biologics's intrinsic value. More Info.
Bone Biologics Corp is rated third in return on equity category among its peers. It is rated fourth in return on asset category among its peers . At this time, Bone Biologics' Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Bone Biologics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Bone Biologics Market Pulse
Quote
20.20
Change(%)
0.00
Change
0.00
Open
20.2
Low
20.2
High
20.2
Volume
0
Exchange
NASDAQ
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Bone Biologics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Bone has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Bone Biologics' financials are consistent with your investment objective using the following steps:
Review Bone Biologics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
Study the cash flow inflows and outflows to understand Bone Biologics' liquidity and solvency.
Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
Compare Bone Biologics' financials to those of its peers to see how it stacks up and identify any potential red flags.
Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Bone Biologics' stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.
Today, most investors in Bone Biologics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bone Biologics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Bone Biologics growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Bone Biologics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Bone Biologics Corp. We use our internally-developed statistical techniques to arrive at the intrinsic value of Bone Biologics Corp based on widely used predictive technical indicators. In general, we focus on analyzing Bone Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bone Biologics's daily price indicators and compare them against related drivers.
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.